Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Foresite Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Foresite Capital

Foresite Capital

Operating

Foresite Capital: A leading US venture capital & growth equity firm, headquartered in San Francisco.

Location
San Francisco, CA, US
Founded
2011
Firm
Compare
Portfolio
Employees
Website

Investments

Remix Therapeutics
Remix Therapeutics

Total Raised

$211M

Rounds

4

Series Unknown$60MJanuary 2024
Series B$70MMay 2022
Odyssey Therapeutics
Odyssey Therapeutics

Total Raised

$487M

Rounds

3

Series C$101MDecember 2023
Series B$168MOctober 2022
Series A$218MDecember 2021
Thyme Care
Thyme Care

Total Raised

$82M

Rounds

2

Series B$60MAugust 2023
Foresight Diagnostics
Foresight Diagnostics

Total Raised

$71.3M

Rounds

4

Series B$58.8MApril 2023
Cerevance
Cerevance

Total Raised

$142.5M

Rounds

5

Series B$51MFebruary 2023
Galileo
Galileo

Total Raised

$114.9k

Rounds

6

Series DDecember 2022
Pleno
Pleno

Total Raised

$55M

Rounds

2

Series A$40MOctober 2022
Folx Health
Folx Health

Total Raised

$59.4M

Rounds

4

Series B$30MOctober 2022
Nested Therapeutics
Nested Therapeutics

Total Raised

$125M

Rounds

2

Series A$90MOctober 2022
Delfi Diagnostics
Delfi Diagnostics

Total Raised

$330.5M

Rounds

3

Series B$225MJuly 2022
Myome
Myome

Total Raised

$23M

Rounds

3

Series B$23MJune 2022
Mirvie
Mirvie

Total Raised

$70.4M

Rounds

4

Series B$45MMay 2022
Kriya Therapeutics
Kriya Therapeutics

Total Raised

$600.5M

Rounds

5

Series C$270MMay 2022
Dnanexus
Dnanexus

Total Raised

$472.6M

Rounds

9

Series H$200MMarch 2022
TenSixteen Bio
TenSixteen Bio

Total Raised

$40M

Rounds

1

Series A$40MJanuary 2022
Immpact Bio
Immpact Bio

Total Raised

$129M

Rounds

2

Series B$111MJanuary 2022
Maze Therapeutics
Maze Therapeutics

Total Raised

$381M

Rounds

3

Series Unknown$190MJanuary 2022
Eikon Therapeutics
Eikon Therapeutics

Total Raised

$772M

Rounds

4

Series B$518MJanuary 2022
Tasso
Tasso
Series B

Total Raised

$135.4M

Rounds

11

Series B$100MDecember 2021
Mythic Therapeutics
Mythic Therapeutics

Total Raised

$126.6M

Rounds

3

Series B$103MDecember 2021
Mammoth Biosciences
Mammoth Biosciences

Total Raised

$264.5M

Rounds

7

Series D$150MSeptember 2021
Tango Therapeutics
Tango Therapeutics
Public

Total Raised

$351M

Rounds

5

Post Ipo Equity$186MAugust 2021